Michael Houghton Acquires 3,202 Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) Stock

Assembly Biosciences, Inc. (NASDAQ:ASMB) Director Michael Houghton bought 3,202 shares of the business’s stock in a transaction on Monday, December 30th. The stock was acquired at an average cost of $15.61 per share, for a total transaction of $49,983.22. Following the completion of the transaction, the director now owns 3,202 shares in the company, valued at $49,983.22. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Assembly Biosciences Trading Down 1.6 %

Shares of NASDAQ ASMB opened at $15.78 on Thursday. The business has a 50 day simple moving average of $16.01 and a 200-day simple moving average of $15.60. Assembly Biosciences, Inc. has a twelve month low of $9.12 and a twelve month high of $19.93.

Analyst Upgrades and Downgrades

A number of research analysts have commented on ASMB shares. HC Wainwright reiterated a “neutral” rating on shares of Assembly Biosciences in a research note on Friday, December 27th. Jefferies Financial Group upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating and upped their target price for the company from $2.00 to $35.00 in a research note on Friday, September 20th.

Institutional Trading of Assembly Biosciences

Institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC grew its position in shares of Assembly Biosciences by 29.7% during the 3rd quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock valued at $240,000 after buying an additional 3,635 shares during the last quarter. Armistice Capital LLC bought a new position in shares of Assembly Biosciences during the second quarter valued at approximately $6,421,000. Acadian Asset Management LLC raised its position in shares of Assembly Biosciences by 131.0% during the 2nd quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company’s stock worth $184,000 after purchasing an additional 7,690 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Assembly Biosciences by 39.2% in the 2nd quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock worth $753,000 after purchasing an additional 15,451 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in Assembly Biosciences by 5,137.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 3,442 shares during the period. 19.92% of the stock is owned by institutional investors and hedge funds.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.